Citius Oncology, Inc. (CTOR) - Net Assets
Based on the latest financial reports, Citius Oncology, Inc. (CTOR) has net assets worth $58.41 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($109.97 Million) and total liabilities ($51.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of Citius Oncology, Inc. for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $58.41 Million |
| % of Total Assets | 53.12% |
| Annual Growth Rate | 7.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 46.96 |
Citius Oncology, Inc. - Net Assets Trend (2022–2025)
This chart illustrates how Citius Oncology, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Citius Oncology, Inc. for the complete picture of this company's asset base.
Annual Net Assets for Citius Oncology, Inc. (2022–2025)
The table below shows the annual net assets of Citius Oncology, Inc. from 2022 to 2025. For live valuation and market cap data, see CTOR market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $44.87 Million | -2.76% |
| 2024-09-30 | $46.14 Million | +80.69% |
| 2023-09-30 | $25.54 Million | -29.59% |
| 2022-09-30 | $36.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Citius Oncology, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5860735700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.35K | 0.02% |
| Other Components | $108.90 Million | 242.72% |
| Total Equity | $44.87 Million | 100.00% |
Citius Oncology, Inc. Competitors by Market Cap
The table below lists competitors of Citius Oncology, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OFX Group Ltd
AU:OFX
|
$80.34 Million |
|
Tacheng Real Estate Co Ltd
TWO:6171
|
$80.34 Million |
|
Country View Bhd
KLSE:5049
|
$80.34 Million |
|
Sekar Laut Tbk
JK:SKLT
|
$80.37 Million |
|
Interlink Communication Public Company Limited
BK:ILINK
|
$80.32 Million |
|
Shinwon
KO:009270
|
$80.31 Million |
|
DTF Tax Free Income Closed Fund
NYSE:DTF
|
$80.28 Million |
|
XAC Automation
TWO:5490
|
$80.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Citius Oncology, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 46,140,339 to 44,866,231, a change of -1,274,108 (-2.8%).
- Net loss of 24,761,369 reduced equity.
- New share issuances of 15,166,842 increased equity.
- Other factors increased equity by 8,320,419.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.76 Million | -55.19% |
| Share Issuances | $15.17 Million | +33.8% |
| Other Changes | $8.32 Million | +18.54% |
| Total Change | $- | -2.76% |
Book Value vs Market Value Analysis
This analysis compares Citius Oncology, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.54x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.35x to 1.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-09-30 | $0.40 | $0.95 | x |
| 2023-09-30 | $0.29 | $0.95 | x |
| 2024-09-30 | $0.64 | $0.95 | x |
| 2025-09-30 | $0.61 | $0.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Citius Oncology, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -55.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.25x
- Recent ROE (-55.19%) is below the historical average (-45.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -29.96% | 0.00% | 0.00x | 1.18x | $-14.49 Million |
| 2023 | -49.72% | 0.00% | 0.00x | 1.87x | $-15.25 Million |
| 2024 | -45.84% | 0.00% | 0.00x | 1.83x | $-25.76 Million |
| 2025 | -55.19% | 0.00% | 0.00x | 2.25x | $-29.25 Million |
Industry Comparison
This section compares Citius Oncology, Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | $58.41 Million | -29.96% | 0.88x | $80.33 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidia… Read more